Start here if you're new
what it is
Immix is developing a CAR-T cell therapy for AL amyloidosis and other serious diseases.
how it gets paid
Last year Immix Biopharma made n/a in revenue. AL amyloidosis program was the main engine at $0M, or 50% of sales.
what just happened
Immix posted -$0.61 EPS last quarter, and revenue was still $0M.
At a glance
C++ balance sheet — some cracks in the foundation
-$0.76 fy2024 eps est
n/a operating margin
1.1 beta
~$522M market cap
xvary composite: 39/100 — weak
What they do
Immix is developing a CAR-T cell therapy for AL amyloidosis and other serious diseases.
You are backing one shot on goal. Immix has 18 employees and one lead program, NXC-201. RMAT → FDA fast lane → so what: the agency gives rare-disease drugs extra attention, and your return depends on that file moving.
How they make money
n/a
annual revenue
AL amyloidosis program
$0M
NXC-201 CAR-T
$0M
NEXICART-2 study
$0M
Other serious diseases
$0M
The products that matter
CAR-T cell therapy
NXC-201
80%+ complete hematologic response in phase 1
it's the only asset on this page that can create future revenue. the 4,000+ new U.S. patients per year figure tells you the commercial prize is targeted, not broad. if you buy IMMX, you are underwriting one therapy in one niche disease setting.
single-asset thesis
Key numbers
-$0.76
fy2024 eps est
n/a
fy rev est
n/a
trailing p/e
n/a
dividend yield
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 4 — safer than 20% of stocks
- price stability 5 / 100
- long-term debt $1M (0% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for IMMX right now.
source: institutional data · return history unavailable
What just happened
missed estimates
Immix posted -$0.61 EPS last quarter, and revenue was still $0M.
EDGAR shows no revenue. shows FY2024 EPS of -$0.76 and an operating margin of -201.0%. That is a loss story waiting for one data readout.
$0M
revenue
-$0.61
eps
n/a
operating margin
the burn rate
The -$0.61 EPS matters because it says the company is still spending before it is selling.
source: and EDGAR, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the risk is not abstract. NXC-201 is the whole equity story on this page, which means weak follow-up data, trial slippage, or ugly financing would all hit the same thesis from different angles.
med
the 80%+ early efficacy signal fades
phase 1 data got the market's attention. later cohorts have to confirm that the signal is durable and repeatable. early biotech numbers often look cleanest before the sample gets larger.
at $0 revenue, there is no second business to soften the blow if the dataset gets messier.
med
cash burn turns into dilution
the company posted a $24M trailing loss and has no commercial sales. that is normal for this stage. it is still a direct threat to your ownership percentage if new capital comes in through equity.
light debt lowers balance-sheet stress. it does not protect you from a financing round at the wrong price.
med
one program means no room for delay
there is no portfolio effect here. enrollment friction, manufacturing issues, or regulatory back-and-forth all land on the same asset that supports the $522M valuation.
when one program carries 100% of the narrative, even a delay can hit the stock like bad data.
these risks sit on top of a $522M market value and a $0 revenue base. if you want certainty, this ticker is in the wrong industry.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
March 23, 2026 earnings and cash update
this is the next hard date on the page. in a pre-revenue biotech, you read the cash balance first and the income statement second.
trend
whether the 80%+ response signal still looks that clean
one strong phase 1 headline created the setup. the next question is durability, depth of response, and whether later data supports the first read.
metric
loss rate versus available funding
the page shows a $24M trailing loss and $0 revenue. if spending rises before the next meaningful catalyst, financing risk moves from background noise to main event.
risk
whether any new capital comes on shareholder-friendly terms
small-cap biotechs survive bad quarters all the time. cheap financing is rarer. if capital is needed, the structure and price will matter almost as much as the amount.
Analyst rankings
risk profile
below average
risk rank 4 — more volatile than most — brace for bigger swings.
chart momentum
average
momentum rank 3 — the stock is moving with the broader market, no unusual signal.
source: institutional data
Institutional activity
institutional ownership data for IMMX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$6
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive